ArticleBMC ophthalmology2025
Functional and structural biomarkers linked to diabetic retinal neurodegeneration in pre-clinical and early diabetic retinopathy.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- KDM6A promotes diabetic retinopathy via H3K27me3-dependent ferroptosis in Müller cells.Cell death & disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic retinal neurodegeneration (DRN) is increasingly recognised as an early and progressive neuronal dysfunction. Despite emerging therapeutic approaches, there are no standardised biomarkers. We aim to investigate functional and structural biomarkers of DRN in people with diabetes (PWD) with no or early diabetic retinopathy (DR).
methodsFunctional measures included handheld radial shape discrimination (hRSD), near and distant visual acuity (VA). Structural changes were evaluated using optical coherence tomography (OCT)-derived retinal thicknesses (Early Treatment Diabetic Retinopathy Study (ETDRS) subfields). Mean thicknesses of the inner and outer ETDRS subfields were averaged to derive inner and outer ring estimates. Pearson’s correlation assessed associations between normally distributed variables. Group differences were analysed using Student’s t-test for continuous data, Chi-squared or Fisher’s exact tests for categorical variables, and one-way ANOVA with Bonferroni-adjusted post hoc tests for multiple groups.
resultsThe study included a single eye from 50 healthy participants (HP; Group 1, 55 ± 14y), 26 PWD with no DR (Group 2, 55 ± 14y), and 46 with early DR (Group 3, 57 ± 17y). hRSD and VA were worse in Groups 1 to 3 (all p < 0.001). Worse function (measured via hRSD) was associated with inner retinal thinning (p < 0.05). Compared to HP, PWD (Groups 2 and 3) showed thinning of the total retina (most subfields), retinal nerve fibre layer (RNFL; outer ETDRS ring), ganglion cell layer (GCL) and inner plexiform layer (IPL) in the inner ring, and outer nuclear layer (ONL) in the central subfield (CSF) (p < 0.05). Group 3 also showed GCL and IPL thinning (outer ring) (p < 0.05). In 23 PWD followed over 205 ± 109 days, GCL, IPL, and inner nuclear layer (INL) thicknesses decreased (p < 0.05).
conclusionsFunctional and structural changes occur early in DR. hRSD and retinal thicknesses are promising biomarkers for DRN. Longitudinal data suggest DRN to be progressive. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.